Avid Bioservices Net Worth
Avid Bioservices Net Worth Breakdown | CDMO |
Avid Bioservices Net Worth Analysis
Avid Bioservices' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Avid Bioservices' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Avid Bioservices' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Avid Bioservices' net worth analysis. One common approach is to calculate Avid Bioservices' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Avid Bioservices' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Avid Bioservices' net worth. This approach calculates the present value of Avid Bioservices' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Avid Bioservices' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Avid Bioservices' net worth. This involves comparing Avid Bioservices' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Avid Bioservices' net worth relative to its peers.
Enterprise Value |
|
To determine if Avid Bioservices is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Avid Bioservices' net worth research are outlined below:
| The company reported the previous year's revenue of 139.91 M. Net Loss for the year was (140.75 M) with profit before overhead, payroll, taxes, and interest of 8.93 M. | |
| Avid Bioservices has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Acquisition by Carleone Joseph of 8147 shares of Avid Bioservices subject to Rule 16b-3 |
Avid Bioservices uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Avid Bioservices. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Avid Bioservices' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 11th of March 2024 Upcoming Quarterly Report | View | |
| 19th of June 2024 Next Financial Report | View | |
| 31st of January 2024 Next Fiscal Quarter End | View | |
| 19th of June 2024 Next Fiscal Year End | View | |
| 31st of October 2023 Last Quarter Report | View | |
| 30th of April 2023 Last Financial Announcement | View |
Avid Bioservices Target Price Consensus
Avid target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Avid Bioservices' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 5 | Buy |
Most Avid analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Avid stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Avid Bioservices, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationAvid Bioservices Target Price Projection
Avid Bioservices' current and average target prices are 12.46 and 12.88, respectively. The current price of Avid Bioservices is the price at which Avid Bioservices is currently trading. On the other hand, Avid Bioservices' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Avid Bioservices Market Quote on 30th of January 2025
Target Price
Analyst Consensus On Avid Bioservices Target Price
Know Avid Bioservices' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Avid Bioservices is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Avid Bioservices backward and forwards among themselves. Avid Bioservices' institutional investor refers to the entity that pools money to purchase Avid Bioservices' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Snyder Capital Management Lp | 2024-09-30 | 1.9 M | Geode Capital Management, Llc | 2024-09-30 | 1.5 M | Emerald Advisers, Llc | 2024-09-30 | 1.4 M | Citadel Advisors Llc | 2024-09-30 | 1.2 M | Harbor Capital Advisors Inc | 2024-09-30 | 1.1 M | Emerald Mutual Fund Advisers Trust | 2024-09-30 | 1.1 M | Point72 (difc) Ltd | 2024-09-30 | 1 M | New York State Common Retirement Fund | 2024-09-30 | 985.9 K | Two Sigma Investments Llc | 2024-09-30 | 827.2 K | Blackrock Inc | 2024-09-30 | 5.3 M | Millennium Management Llc | 2024-09-30 | 4.2 M |
Follow Avid Bioservices' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 795.7 M.Market Cap |
|
Project Avid Bioservices' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.38) | (0.40) | |
| Return On Capital Employed | (0.06) | (0.07) | |
| Return On Assets | (0.38) | (0.40) | |
| Return On Equity | (2.66) | (2.53) |
When accessing Avid Bioservices' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Avid Bioservices' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Avid Bioservices' profitability and make more informed investment decisions.
Evaluate Avid Bioservices' management efficiency
Avid Bioservices has return on total asset (ROA) of (0.0305) % which means that it has lost $0.0305 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1584) %, meaning that it created substantial loss on money invested by shareholders. Avid Bioservices' management efficiency ratios could be used to measure how well Avid Bioservices manages its routine affairs as well as how well it operates its assets and liabilities. As of the 30th of January 2025, Return On Tangible Assets is likely to drop to -0.4. In addition to that, Return On Capital Employed is likely to drop to -0.07. At this time, Avid Bioservices' Other Assets are very stable compared to the past year. As of the 30th of January 2025, Net Tangible Assets is likely to grow to about 228.8 M, while Return On Tangible Assets are likely to drop (0.40).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.11 | 1.05 | |
| Tangible Book Value Per Share | 1.11 | 1.05 | |
| Enterprise Value Over EBITDA | (65.30) | (62.04) | |
| Price Book Value Ratio | 7.13 | 5.38 | |
| Enterprise Value Multiple | (65.30) | (62.04) | |
| Price Fair Value | 7.13 | 5.38 | |
| Enterprise Value | 212.3 M | 222.9 M |
Avid Bioservices has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Enterprise Value Revenue 6.4288 | Revenue | Quarterly Revenue Growth 0.065 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Avid Bioservices insiders, such as employees or executives, is commonly permitted as long as it does not rely on Avid Bioservices' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Avid Bioservices insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Avid Bioservices Corporate Filings
F4 | 29th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 23rd of January 2025 Other Reports | ViewVerify | |
| 14th of January 2025 Other Reports | ViewVerify | |
| 18th of December 2024 Other Reports | ViewVerify |
Avid Bioservices Earnings Estimation Breakdown
The calculation of Avid Bioservices' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Avid Bioservices is estimated to be -0.04 with the future projection ranging from a low of -0.04 to a high of -0.04. Please be aware that this consensus of annual earnings estimates for Avid Bioservices is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.04 Lowest | Expected EPS | -0.04 Highest |
Avid Bioservices Earnings Projection Consensus
Suppose the current estimates of Avid Bioservices' value are higher than the current market price of the Avid Bioservices stock. In this case, investors may conclude that Avid Bioservices is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Avid Bioservices' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of January 2025 | Current EPS (TTM) | |
| 5 | 44.93% | -0.2727 | -0.04 | -2.41 |
Avid Bioservices Earnings per Share Projection vs Actual
Actual Earning per Share of Avid Bioservices refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Avid Bioservices predict the company's earnings will be in the future. The higher the earnings per share of Avid Bioservices, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Avid Bioservices Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Avid Bioservices, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Avid Bioservices should always be considered in relation to other companies to make a more educated investment decision.Avid Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Avid Bioservices' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-12-05 | 2024-10-31 | -0.1 | -0.2727 | -0.1727 | 172 | ||
2024-09-09 | 2024-07-31 | -0.05 | -0.09 | -0.04 | 80 | ||
2024-07-02 | 2024-04-30 | -0.04 | -1.94 | -1.9 | 4750 | ||
2024-03-07 | 2024-01-31 | -0.05 | -0.05 | 0.0 | 0 | ||
2023-12-07 | 2023-10-31 | -0.06 | -0.15 | -0.09 | 150 | ||
2023-09-07 | 2023-07-31 | -0.03 | -0.03 | 0.0 | 0 | ||
2023-06-21 | 2023-04-30 | -0.01 | 0.0505 | 0.0605 | 605 | ||
2023-03-13 | 2023-01-31 | -0.04 | 0.01 | 0.05 | 125 | ||
2022-12-06 | 2022-10-31 | 0.0175 | -0.02 | -0.0375 | 214 | ||
2022-09-06 | 2022-07-31 | 0.04 | 0.02 | -0.02 | 50 | ||
2022-06-29 | 2022-04-30 | 0.01 | 0.01 | 0.0 | 0 | ||
2022-03-08 | 2022-01-31 | 0.04 | 0.04 | 0.0 | 0 | ||
2021-12-07 | 2021-10-31 | 0.03 | 0.06 | 0.03 | 100 | ||
2021-09-08 | 2021-07-31 | 0.04 | 0.1 | 0.06 | 150 | ||
2021-06-29 | 2021-04-30 | 0.01 | -0.04 | -0.05 | 500 | ||
2021-03-08 | 2021-01-31 | -0.03 | 0.01 | 0.04 | 133 | ||
2020-12-02 | 2020-10-31 | -0.06 | 0.01 | 0.07 | 116 | ||
2020-09-01 | 2020-07-31 | -0.07 | 0.06 | 0.13 | 185 | ||
2020-06-30 | 2020-04-30 | -0.16 | -0.11 | 0.05 | 31 | ||
2020-03-10 | 2020-01-31 | -0.04 | -0.06 | -0.02 | 50 | ||
2019-12-09 | 2019-10-31 | -0.05 | -0.03 | 0.02 | 40 | ||
2019-09-05 | 2019-07-31 | -0.03 | -0.08 | -0.05 | 166 | ||
2019-06-27 | 2019-04-30 | -0.03 | -0.02 | 0.01 | 33 | ||
2019-03-11 | 2019-01-31 | -0.07 | -0.05 | 0.02 | 28 | ||
2018-12-10 | 2018-10-31 | -0.08 | -0.05 | 0.03 | 37 | ||
2018-09-10 | 2018-07-31 | -0.13 | -0.06 | 0.07 | 53 | ||
2018-07-16 | 2018-04-30 | -0.15 | 0.05 | 0.2 | 133 | ||
2018-03-12 | 2018-01-31 | -0.14 | -0.28 | -0.14 | 100 | ||
2017-12-11 | 2017-10-31 | -0.12 | -0.28 | -0.16 | 133 | ||
2017-09-11 | 2017-07-31 | -0.12 | -0.06 | 0.06 | 50 | ||
2017-07-14 | 2017-04-30 | -0.07 | -0.16 | -0.09 | 128 | ||
2017-03-13 | 2017-01-31 | -0.21 | -0.28 | -0.07 | 33 | ||
2016-12-12 | 2016-10-31 | -0.19 | -0.14 | 0.05 | 26 | ||
2016-09-08 | 2016-07-31 | -0.28 | -0.35 | -0.07 | 25 | ||
2016-07-14 | 2016-04-30 | -0.23 | -0.35 | -0.12 | 52 | ||
2016-03-09 | 2016-01-31 | -0.51 | -0.56 | -0.05 | 9 | ||
2015-12-10 | 2015-10-31 | -0.61 | -0.49 | 0.12 | 19 | ||
2015-09-09 | 2015-07-31 | -0.54 | -0.56 | -0.02 | 3 | ||
2015-07-14 | 2015-04-30 | -0.54 | -0.49 | 0.05 | 9 | ||
2015-03-12 | 2015-01-31 | -0.56 | -0.56 | 0.0 | 0 | ||
2014-12-10 | 2014-10-31 | -0.51 | -0.49 | 0.02 | 3 | ||
2014-09-09 | 2014-07-31 | -0.42 | -0.56 | -0.14 | 33 | ||
2014-07-14 | 2014-04-30 | -0.47 | -0.42 | 0.05 | 10 | ||
2014-03-07 | 2014-01-31 | -0.44 | -0.42 | 0.02 | 4 | ||
2013-12-10 | 2013-10-31 | -0.35 | -0.35 | 0.0 | 0 | ||
2013-09-09 | 2013-07-31 | -0.33 | -0.35 | -0.02 | 6 | ||
2013-07-11 | 2013-04-30 | -0.4 | -0.42 | -0.02 | 5 | ||
2013-03-12 | 2013-01-31 | -0.47 | -0.28 | 0.19 | 40 | ||
2012-12-10 | 2012-10-31 | -0.63 | -0.42 | 0.21 | 33 | ||
2012-09-10 | 2012-07-31 | -0.75 | -0.49 | 0.26 | 34 | ||
2012-07-16 | 2012-04-30 | -0.89 | -0.7 | 0.19 | 21 | ||
2012-03-09 | 2012-01-31 | -0.91 | -0.91 | 0.0 | 0 | ||
2011-12-12 | 2011-10-31 | -0.96 | -1.12 | -0.16 | 16 | ||
2011-09-09 | 2011-07-31 | -1.01 | -0.77 | 0.24 | 23 | ||
2011-07-14 | 2011-04-30 | -1.05 | -1.05 | 0.0 | 0 | ||
2010-12-09 | 2010-10-31 | -0.75 | -0.91 | -0.16 | 21 | ||
2010-09-09 | 2010-07-31 | -0.74 | -0.98 | -0.24 | 32 | ||
2010-07-14 | 2010-04-30 | -0.65 | -1.12 | -0.47 | 72 | ||
2010-03-11 | 2010-01-31 | -0.36 | -0.21 | 0.15 | 41 | ||
2009-12-10 | 2009-10-31 | -0.08 | -0.42 | -0.34 | 425 | ||
2009-09-03 | 2009-07-31 | -0.12 | -0.35 | -0.23 | 191 | ||
2009-07-14 | 2009-04-30 | 0.16 | -0.14 | -0.3 | 187 | ||
2009-03-12 | 2009-01-31 | -0.07 | -0.07 | 0.0 | 0 | ||
2008-12-10 | 2008-10-31 | -0.14 | -0.14 | 0.0 | 0 | ||
2008-09-09 | 2008-07-31 | -0.14 | -0.14 | 0.0 | 0 | ||
2008-07-14 | 2008-04-30 | -0.21 | -0.14 | 0.07 | 33 | ||
2008-03-11 | 2008-01-31 | -0.21 | -0.21 | 0.0 | 0 |
Avid Bioservices Corporate Management
| Mark JD | General VP | Profile | |
| Daniel Hart | Chief Officer | Profile | |
| Oksana Lukash | Vice People | Profile | |
| Prof Brekken | Medical Advisor | Profile | |
| Harold MD | Medical Advisor | Profile | |
| Prof Schroit | Medical Advisor | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avid Bioservices. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Avid Stock, please use our How to Invest in Avid Bioservices guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avid Bioservices. If investors know Avid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avid Bioservices listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.80) | Earnings Share (2.41) | Revenue Per Share | Quarterly Revenue Growth 0.065 | Return On Assets |
The market value of Avid Bioservices is measured differently than its book value, which is the value of Avid that is recorded on the company's balance sheet. Investors also form their own opinion of Avid Bioservices' value that differs from its market value or its book value, called intrinsic value, which is Avid Bioservices' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avid Bioservices' market value can be influenced by many factors that don't directly affect Avid Bioservices' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avid Bioservices' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avid Bioservices is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avid Bioservices' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.